Edition:
United States

Tyme Technologies Inc (TYME.OQ)

TYME.OQ on NASDAQ Stock Exchange Capital Market

2.59USD
15 Oct 2018
Change (% chg)

$0.06 (+2.37%)
Prev Close
$2.53
Open
$2.52
Day's High
$2.70
Day's Low
$2.52
Volume
6,211
Avg. Vol
95,465
52-wk High
$8.27
52-wk Low
$2.01

Latest Key Developments (Source: Significant Developments)

FDA Acceptance Of IND For Tyme To Begin Phase II Trial In Pancreatic Cancer
Wednesday, 14 Mar 2018 08:00am EDT 

March 14 (Reuters) - Tyme Technologies Inc ::FDA ACCEPTANCE OF IND FOR TYME TO BEGIN PHASE II TRIAL IN PANCREATIC CANCER.TYME TECHNOLOGIES INC - EXPECTS INITIAL CLINICAL SITES TO BEGIN ENROLLING PATIENTS OVER NEXT FEW WEEKS IN PHASE II TRIAL.TYME TECHNOLOGIES INC - ‍ FINAL DATA FROM AN ONGOING PHASE II CLINICAL TRIAL EVALUATING SM-88 FOR PROSTATE CANCER EXPECTED AROUND YEAR-END 2018​.  Full Article

Tyme Technologies prices offering of 9 mln shares at $2.25 a share
Thursday, 1 Mar 2018 09:45pm EST 

March 1 (Reuters) - Tyme Technologies Inc ::TYME TECHNOLOGIES ANNOUNCES PRICING OF ITS OFFERING OF 9 MILLION SHARES OF COMMON STOCK.TYME TECHNOLOGIES - ‍PRICED ITS UNDERWRITTEN PUBLIC OFFERING OF 9 MILLION SHARES OF ITS COMMON STOCK, AT A PUBLIC OFFERING PRICE OF $2.25 PER SHARE​.  Full Article

Tyme Technologies Announces Offering Of Common Stock Of Up To 12 Million Shares
Monday, 26 Feb 2018 04:01pm EST 

Feb 26 (Reuters) - Tyme Technologies Inc ::TYME TECHNOLOGIES ANNOUNCES OFFERING OF COMMON STOCK.TYME TECHNOLOGIES - COMMENCED UNDERWRITTEN PUBLIC OFFERING OF UP TO 12 MILLION SHARES OF ITS COMMON STOCK, PAR VALUE $0.0001 PER SHARE.  Full Article

Tyme Provides Update On At-The-Market Financing Activity
Tuesday, 5 Dec 2017 08:00am EST 

Dec 5 (Reuters) - Tyme Technologies Inc ::TYME PROVIDES UPDATE ON AT-THE-MARKET FINANCING ACTIVITY.TYME TECHNOLOGIES INC - HAS RAISED GROSS PROCEEDS OF APPROXIMATELY $5.0 MILLION FROM ITS AT-THE-MARKET FINANCING FACILITY.  Full Article

Tyme reports encouraging efficacy and safety data from first human study of sm-88
Monday, 6 Nov 2017 08:00am EST 

Nov 6 (Reuters) - Tyme Technologies Inc ::Tyme announces encouraging efficacy and safety data from first human study of sm-88 in women with metastatic breast cancer.Tyme Technologies Inc - ‍no drug-related serious adverse events were observed during sm-88 therapy​.Tyme Technologies Inc - ‍43 percent of patients demonstrated complete or partial responses while on monotherapy during study of sm-88​.  Full Article

Tyme Technologies files for mixed shelf offering of up to $250 mln
Thursday, 14 Sep 2017 04:52pm EDT 

Sept 15 (Reuters) - Tyme Technologies Inc :Tyme Technologies Inc files for mixed shelf offering of up to $250 million - SEC filing‍​.  Full Article

TYME Technologies inc files for mixed shelf of upto $250 million - SEC Filing
Tuesday, 8 Aug 2017 05:35pm EDT 

Aug 8 (Reuters) - TYME Technologies Inc :TYME Technologies Inc files for mixed shelf of upto $250 million - SEC Filing.  Full Article